




The relative strengths and weaknesses of Regulus Therapeutics Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Regulus Therapeutics Inc compared to the market average is the variable Stockholders Equity, increasing the Economic Capital Ratio by 63% points. The greatest weakness of Regulus Therapeutics Inc is the variable Liabilities, Non-Current, reducing the Economic Capital Ratio by 23% points.

The company's Economic Capital Ratio, given in the ranking table, is 319%, being 44% points above the market average of 275%.

Input Variable	Value in 1000 USD	Output Variable	Value in 1000 USD
Assets, Current	65,235	Assets	68,454
Cost of Goods Sold	0	Liabilities	13,496
Intangible Assets	83	Expenses	28,672
Liabilities, Current	5,227	Revenues	864
Liabilities, Non-Current	8,269	Stockholders Equity	54,958
Other Assets	3,136	Net Income	-27,808
Other Compr. Net Income	0	Comprehensive Net Income	-27,808
Other Expenses	856	BaseVar	55,743
Other Liabilities	0	ECR before LimitedLiability	225%
Other Net Income	0	Economic Capital Ratio	319%
Other Revenues	864		
Property and Equipment	0		
Research and Development	17,794		
Selling, General and Administrative Expense	10,022		